Full Text View
Tabular View
No Study Results Posted
Related Studies
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
This study is currently recruiting participants.
Study NCT00837148   Information provided by Memorial Sloan-Kettering Cancer Center
First Received: February 4, 2009   Last Updated: February 5, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
Synovial Sarcoma
Leiomyosarcoma
Additional conditions recognized in this trial
Nerve Sheath Neoplasms
Sarcoma, Synovial
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Neoplasms, Nerve Tissue
Nervous System Diseases
Nervous System Neoplasms
Neuromuscular Diseases
Peripheral Nervous System Diseases
Peripheral Nervous System Neoplasms
Interventions listed in this trial
Sorafenib and Dacarbazine
Additional drug interventions recognized in this trial
Dacarbazine
Sorafenib
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services